相关实验视频

Updated: Sep 15, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

通过DTI-ALPS指数评估的淋巴功能障碍通过粉样蛋白β依赖途径调解阿尔茨海默氏症的认知衰退:多式PET/MRI研究

Yan Zhang¹, Gan Huang¹, Jieli Geng²

¹Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.

European journal of nuclear medicine and molecular imaging

|July 18, 2025

概括

通过沿周血管空间 (DTI-ALPS) 进行扩散张力成像测量的淋巴功能障碍,主要通过粉样β途径驱动阿尔茨海默病的进展. 与晚期发病的AD相比,早期发病的AD显示出独特的神经成像-认知联系.

科学领域:

神经成像和神经退化
淋巴系统功能淋巴系统功能
阿尔茨海默病病理生理病理学

背景情况:

淋巴功能障碍与阿尔茨海默病 (AD) 的进展有关.
沿周血管空间的扩散张力成像 (DTI-ALPS) 量化周血管功能.
在阿尔茨海默氏症中,淋巴功能,粉样β (Aβ) 和tau之间的相互作用尚未完全理解.

研究的目的:

调查DTI-ALPS指数是否调解与AD相关的认知衰退.
探索Aβ和tau通路在这种调解中的作用.
使用同步三标记器PET/MRI进行全面的生物标志物分析.

主要方法:

对140名年龄在61-74岁的参与者 (AD,MCI,SCD) 的回顾性分析.
同时使用DTI-ALPS进行[18F]Florbetapir (Aβ),[18F]PI-2620 (tau) 和[18F]FDG PET/MRI.
为评估生物标志物关系进行因果调解分析 (P < 0.05).

主要成果:

在临床阶段,ALPS指数逐渐下降 (SCD>MCI>AD).
较低的ALPS与较高的Aβ-PET,tau-PET和较低的FDG-PET相关.
Aβ-PET完全调解了ALPS对认知和大脑新陈代谢的影响,独立于tau.
早期发病的AD (EOAD) 与晚期发病的AD (LOAD) 相比,显示出明显的ALPS认知关系.

结论:

DTI-ALPS量化了导致AD进展的淋巴功能障碍.
主要途径涉及Aβ依赖机制,影响认知和新陈代谢.
在EOAD和LOAD之间存在明显的神经成像-认知关系.

关键词:

阿尔卑斯山的阿尔卑斯山.阿尔茨海默病的疾病阿尔茨海默病的疾病.粉样蛋白是什么粉样蛋白是什么德国联邦航空公司 (FDG)定子发射断层扫描 (PET) 是一种定子发射断层扫描.塔乌·塔乌 (Tau Tau) 是一个

更多相关视频

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...